Table 2

Migration of pancreatic cancer cells enhanced by IL-1α and its suppresion by anti-integrin, anti-uPAR antibodies

Pancreatic cancer cells (number of migrated cells)


BxPC-3

Capan-2

SW1990


Control

32.0 ± 6.24

(0)

27.7 ± 3.09

(0)

33.3 ± 3.09

(0)

IL-1α

59.2 ± 6.65 a

(184.9)

47.0 ± 7.13 a

(170.0)

63.2 ± 7.13 a

(189.5)

IL-1α + IgG

58.3 ± 8.69 a

(182.3)

45.8 ± 6.82 a

(165.7)

62.5 ± 6.82 a

(187.5)

anti-α6 integrin

21.0 ± 1.35 a

(65.6)

19.9 ± 2.21 a

(71.8)

23.6 ± 2.48 a

(70.9)

IL-1α + anti-α6 integrin

23.0 ± 2.45 a

(71.9)

22.3 ± 3.34 a

(80.1)

23.3 ± 3.34 a

(70.0)

anti-β1 integrin

21.1 ± 1.35 a

(65.9)

23.3 ± 1.41 a

(84.1)

22.1 ± 2.14 a

(66.4)

IL-1α + anti-β1 integrin

23.7 ± 2.05 a

(74.0)

22.5 ± 2.75 a

(81.3)

23.7 ± 2.75 a

(71.0)

anti-uPAR

25.2 ± 2.31 a

(78.8)

20.1 ± 2.07 a

(72.6)

24.1 ± 1.18 a

(72.4)

IL-1α + anti-uPAR

24.5 ± 4.28 a

(76.6)

21.2 ± 2.48 a

(76.5)

24.8 ± 2.48 a

(76.5)


IL-1α, interleukin-1α; uPAR, urokinase plasminogen activator receptor. All data are expressed as mean ± s.d. (% increase). The p-values indicate statistical significance between data in controls and presence of IL-α with/without respective antibodies. a p < 0.05.

Sawai et al. BMC Cell Biology 2006 7:8   doi:10.1186/1471-2121-7-8

Open Data